Skip to main content
SpringerLink
Log in
Book cover

Micrometastasis pp 87–116Cite as

Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow

  • Chapter

Part of the Cancer Metastasis - Biology and Treatment book series (CMBT,volume 5)

Abstract

About 20% to 40% of men who undergo a radical prostatectomy for localized prostate cancer will relapse with progressive disease that frequently results in bone metastases. In addition to numerous studies of the primary tumour, there has been increased attention paid to disseminated cells shed by the tumour and detected in the peripheral blood and bone marrow. It would appear logical that the prostate cancer cells in the blood and the bone marrow that remain following a radical prostatectomy may be more informative in revealing prognostic information than those of the primary tumour which is removed at surgery. The evidence for existence of these disseminated cells in the peripheral blood and bone marrow of prostate cancer patients was first described in the early 1990s using a prostate specific antigen reverse transcriptase polymerase chain reaction (PSA RT-PCR). In general, these studies revealed the presence of disseminated PSA+ epithelial cells (presumed to be prostate cancer cells) early in the disease course and more prevalent in advanced disease than in early disease. Most showed that the bone marrow was more frequently positive than the peripheral blood. As a staging tool, these studies generally showed that PSA RT-PCR was not highly informative since even patients with low stage and early disease frequently showed evidence of disseminated PSA+ cells. Over the past few years, there has been a rapid development of technologies for isolating these disseminated cells for further study. The first step was the enrichment of circulating tumour cells, followed by attempts to isolate and characterize individual cells. The enriched cells have been analysed by a variety of methods, including flow cytometry, immunohistochemistry, and fluorescent in situ hybridisation. Biological characterisation of the cells have included the assessment of telomerase activity, androgen receptor status, and genomic alterations such as loss of heterozygosity and microsatellite instability. Attempts are under way to extend this analysis by utilizing gene expression micro-arrays and array Comparative Genomic Hybridisation (array-CGH). Although these efforts encompass challenges much will be learned about the character of these disseminated cells, including their process of trafficking to distant sites, their potential to seed and grow at these sites and their tendencies for cell dormancy.

Keywords

  • Prostate Cancer
  • Prostate Cancer Cell
  • Radical Prostatectomy
  • Reverse Transcriptase Polymerase Chain Reaction
  • Prostate Cancer Patient

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 15–36.

    PubMed  CAS  Google Scholar 

  2. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update. 2001 — testing for early lung cancer detection. CA Cancer J Clin. 2001; 51: 38–75.

    PubMed  CAS  Google Scholar 

  3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997; 47: 5–27.

    CrossRef  PubMed  CAS  Google Scholar 

  4. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer. 1998; 82: 1419–1442.

    CrossRef  PubMed  CAS  Google Scholar 

  5. Pienta KJ. Etiology, epidemiology, and prevention of carcinoma of the prostate. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell’s Urology. New York: Saunders; 1997, pp. 2489–2496.

    Google Scholar 

  6. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555–565.

    CrossRef  PubMed  CAS  Google Scholar 

  7. Lepor H. Radical retropubic prostatectomy. Urol Clin North Am. 2001; 28: 509–519, viii.

    PubMed  CAS  Google Scholar 

  8. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000; 55: 58–61.

    PubMed  CAS  Google Scholar 

  9. Gallucci M, Vincenzoni A. Laparoscopic radical prostatectomy: a marketing or surgical strategy? Curr Opin Urol. 2001; 11: 305–308.

    CrossRef  PubMed  CAS  Google Scholar 

  10. Olsson LE, Salomon L, Nadu A, Hoznek A, Cicco A, Saint F, Chopin D, Abbou CC. Prospective patient-reported continence after laparoscopic radical prostatectomy. Urology. 2001; 58: 570–572.

    CrossRef  PubMed  CAS  Google Scholar 

  11. Turk I, Deger S, Winkelmann B, Schonberger B, Loening SA. Laparoscopic Radical Prostatectomy. Technical aspects and experience with 125 cases. Eur Urol. 2001; 40: 46–53.

    PubMed  CAS  Google Scholar 

  12. Turk I, Deger IS, Winkelmann B, Roigas J, Schonberger B, Loening SA. [Laparoscopic radical prostatectomy. Experiences with 145 interventions]. Urologe A. 2001; 40: 199–206.

    PubMed  CAS  Google Scholar 

  13. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001; 51: 614–623.

    PubMed  CAS  Google Scholar 

  14. Siegsmund M, Musial A, Weiss J, Alken P. [Ldr brachytherapy, a minimally invasive alternative in the treatment of organ-confined prostate cancer]. Onkologie. 2001; 24Suppl 5: 46–50.

    PubMed  Google Scholar 

  15. Dejter SW, Jr, Cunningham RE, Noguchi PD, Jones RV, Moul JW, McLeod DG, Lynch JH. Prognostic significance of DNA ploidy in carcinoma of prostate. Urology. 1989; 33: 361–366.

    CrossRef  PubMed  Google Scholar 

  16. Kasahara K, Taguchi T, Yamasaki I, Karashima T, Kamada M, Yuri K, Shuin T. Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy. Int J Oncol. 2001; 19: 543–549.

    PubMed  CAS  Google Scholar 

  17. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 1994; 54: 3998–4002.

    PubMed  CAS  Google Scholar 

  18. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Clin Cancer Res. 1996; 2: 137–145.

    PubMed  CAS  Google Scholar 

  19. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996; 156: 137–143.

    PubMed  CAS  Google Scholar 

  20. Bretton PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate. 1994; 25: 108–114.

    PubMed  CAS  Google Scholar 

  21. Kollermann J, Heseding B, Helpap B, Kollermann MW, Pantel K. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int J Cancer. 1999; 84: 145–149.

    PubMed  CAS  Google Scholar 

  22. Pantel K, Aignherr C, Kollermann J, Caprano J, Riethmuller G, Kollermann MW. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer. 1995; 31A: 1627–1632.

    PubMed  CAS  Google Scholar 

  23. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996; 347: 649–653.

    CrossRef  PubMed  CAS  Google Scholar 

  24. Pantel K, Enzmann T, Kollermann J, Caprano J, Riethmuller G, Kollermann MW. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer. 1997; 71: 521–525.

    CrossRef  PubMed  CAS  Google Scholar 

  25. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O’Toole K, McMahon D, Benson MC, Katz AE. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol. 1995; 153: 1373–1378.

    PubMed  CAS  Google Scholar 

  26. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CY, Ellis WJ, Vessella RL. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology. 1997; 50: 184–188.

    PubMed  CAS  Google Scholar 

  27. Corey E, Corey MJ. Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): technical and clinical aspects. Int J Cancer. 1998; 77: 655–673.

    CrossRef  PubMed  CAS  Google Scholar 

  28. Ghossein RA, Carusone L, Bhattacharya S. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas. In Vivo. 2000; 14: 237–250.

    PubMed  CAS  Google Scholar 

  29. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH, Vessella RL. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res. 1997; 3: 249–256.

    PubMed  CAS  Google Scholar 

  30. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992; 52: 6110–6112.

    PubMed  CAS  Google Scholar 

  31. Oefelein MG, Kaul K, Herz B, Blum MD, Holland JM, Keeler TC, Cook WA, Ignatoff JM. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol. 1996; 155: 238–242.

    PubMed  CAS  Google Scholar 

  32. Olsson CA, de Vries GM, Raffo AJ, Benson MC, O’Toole K, Cao Y, Buttyan RE, Katy AE. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996; 155: 1557–1562.

    PubMed  CAS  Google Scholar 

  33. Vessella RL, Riley DE, Blouke KA, Arfman EW, Lange PH. A sensitive method for detection of a prostate tumor cell marker using the polymerase chain reaction. J Urol. 1992; 147 suppl.: 441A.

    Google Scholar 

  34. Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Detection of prostate-specific antigen-or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications. Eur Urol. 1999; 36: 278–285.

    CrossRef  PubMed  CAS  Google Scholar 

  35. Su SL, Heston WD, Perrotti M, Cookson MS, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair WR, Perroti M. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997; 49: 95–101.

    CrossRef  PubMed  CAS  Google Scholar 

  36. Ellis WJ, Vessella RL, Corey E, Arfman EW, Oswin MM, Melchior S, Lange PH. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol. 1998; 159: 1134–1138.

    PubMed  CAS  Google Scholar 

  37. Bianco FJ, Jr, Wood DP, Jr, Gomes DO, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate. 2001; 49: 235–242.

    CrossRef  PubMed  Google Scholar 

  38. Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ. Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol. 2001; 166: 1316–1321.

    PubMed  CAS  Google Scholar 

  39. Gong MC, Chang SS, Watt F, O’Keefe DS, Bacich DJ, Uchida A, Bander NH, Reuter VE, Gaudin PB, Molloy PL, Sadelian M, Heston WD. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol. 2000; 4: 217–222.

    CrossRef  PubMed  CAS  Google Scholar 

  40. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol. 1976; nSuppl. 5: 9–15.

    Google Scholar 

  41. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand J Immunol. 1991; 34: 697–712.

    PubMed  CAS  Google Scholar 

  42. Berteau P, Dumas F, Gala JL, Eschwege P, Lacour B, Philippe M, Loric S. Molecular detection of circulating prostate cells in cancer II: Comparison of prostate epithelial cells isolation procedures. Clin Chem. 1998; 44: 1750–1753.

    PubMed  CAS  Google Scholar 

  43. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts’o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer. 2000; 88: 2787–2795.

    PubMed  CAS  Google Scholar 

  44. Molino A, Colombatti M, Bonetti F, Zardini M, Pasini F, Perini A, Pelosi G, Tridente G, Veneri D, Cetto GL. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer. 1991; 67: 1033–1036.

    PubMed  CAS  Google Scholar 

  45. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 1987; 84: 8672–8676.

    PubMed  CAS  ADS  Google Scholar 

  46. Oberneder R, Riesenberg R, Kriegmair M, Bitzer U, Klammert R, Schneede P, Hofstetter A, Riethmuller G, Pantel K. Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res. 1994; 22: 3–8.

    CrossRef  PubMed  CAS  Google Scholar 

  47. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994; 3: 165–173.

    PubMed  CAS  Google Scholar 

  48. Pantel K, Riethmuller G. Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol. 1996; 213 (Pt 3): 1–18.

    PubMed  CAS  Google Scholar 

  49. Müller P, Carroll P, Bowers E, Moore D, Cher M, Presti J, Wessman M, Pallavicini MG. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer. 1998; 83: 538–546.

    Google Scholar 

  50. Müller P, Weckermann D, Riethmuller G, Schlimok G. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1996; 88: 8–16.

    PubMed  Google Scholar 

  51. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol. 1998; 160: 2396–2401.

    PubMed  CAS  Google Scholar 

  52. Pantel K, Schlimok G, Angstwurm M, Passlick B, Izbicki JR, Johnson JP, Riethmuller G. Early metastasis of human solid tumours: expression of cell adhesion molecules. Ciba Found Symp. 1995; 189: 157–170.

    PubMed  CAS  Google Scholar 

  53. Weckermann D, Müller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol. 1999; 17: 3438–3443.

    PubMed  CAS  Google Scholar 

  54. Weckermann D, Wawroschek F, Krawczak G, Haude KH, Harzmann R. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy? Urol Res. 1999; 27: 285–290.

    CrossRef  Google Scholar 

  55. Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001; 166: 699–703.

    PubMed  CAS  Google Scholar 

  56. Fordham MV, Burdge AH, Matthews J, Williams G, Cooke T. Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome. Brit J Surg. 1986; 73: 400–403.

    PubMed  CAS  Google Scholar 

  57. Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol. 1988; 140: 769–774.

    PubMed  CAS  Google Scholar 

  58. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, Lange PH, Higano CS, Hood L, van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate. 1999; 40: 192–199.

    CrossRef  PubMed  Google Scholar 

  59. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res. 2000; 60: 3429–3434.

    PubMed  CAS  Google Scholar 

  60. Liu AY, Peehl DM. Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res. 2001; 305: 389–397.

    PubMed  CAS  Google Scholar 

  61. Barren RJ, III, Holmes EH, Boynton AL, Gregorakis A, Elgamal AA, Cobb OE, Wilson CL, Ragde H, Murphy GP. Method for identifying prostate cells in semen using flow cytometry. Prostate. 1998; 36: 181–188.

    CrossRef  PubMed  Google Scholar 

  62. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Brit J Urol. 1992; 69: 392–396.

    CrossRef  PubMed  CAS  Google Scholar 

  63. Fadlon EJ, Rees RC, McIntyre C, Sharrard RM, Lawry J, Hamdy FC. Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Brit J Cancer. 1996; 74: 400–405.

    PubMed  CAS  Google Scholar 

  64. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, Assmann G, Zanker KS. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 1996; 56: 4556–4561.

    PubMed  CAS  Google Scholar 

  65. De La Taille, Muscatelli B, Colombel M, Jouault H, Amsellem S, Mazeman E, Abbou CC, Chopin D. [In vitro detection of prostate cancer circulating cells by immunocytochemistry, flow cytometry and RT-PCR PSA]. Prog Urol. 1998; 8: 1058–1064.

    PubMed  Google Scholar 

  66. De La Taille, Salomon L, Colombel M, Abbou CC, Chopin D, Groux-Muscatelli B. [Detection of circulating prostatic cells with RT-PCR PSA in prostatic cancer]. Prog Urol. 1999; 9: 1084–1089.

    PubMed  Google Scholar 

  67. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998; 95: 4589–4594.

    CrossRef  PubMed  CAS  ADS  Google Scholar 

  68. Moreno JG, O’Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001; 58: 386–392.

    CrossRef  PubMed  CAS  Google Scholar 

  69. Kostler WJ, Brodowicz T, Hejna M, Wiltschke C, Zielinski CC. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences. Cancer Detect Prev. 2000; 24: 376–403.

    PubMed  CAS  Google Scholar 

  70. Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn Mol Pathol. 1999; 8: 165–175.

    PubMed  CAS  Google Scholar 

  71. Olsson CA, de Vries GM, Benson MC, Raffo A, Buttyan R, Cama C, O’Toole K, Katz AE. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Brit J Urol. 1996; 77: 411–417.

    PubMed  CAS  Google Scholar 

  72. Wood DP, Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 1997; 15: 3451–3457.

    PubMed  Google Scholar 

  73. Katz AE, de Vries GM, Benson MC, Buttyan RE, O’Toole K, Rubin MA, Stifelman M, Olsson CA. The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am. 1996; 23: 541–549.

    CrossRef  PubMed  CAS  Google Scholar 

  74. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994; 78: 1536–1539.

    CrossRef  PubMed  CAS  Google Scholar 

  75. Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Brit J Cancer. 1996; 74: 871–873.

    PubMed  CAS  Google Scholar 

  76. Levesque M, Hu H, D’Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal. 1995; 9: 123–128.

    PubMed  CAS  Google Scholar 

  77. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate. 1997; 32: 140–148.

    CrossRef  PubMed  CAS  Google Scholar 

  78. Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res. 1997; 57: 4167–4170.

    PubMed  CAS  Google Scholar 

  79. Cama C, Olsson CA, Buttyan R, de Vries GM, Wise GJ, Katz AE. Molecular staging of prostate cancer. III. Effects of cystoscopy and needle biopsy on the enhanced reverse transcriptase polymerase chain reaction assay. J Urol. 1997; 157: 1748–1751.

    PubMed  CAS  Google Scholar 

  80. Israeli RS, Miller WH, Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 1994; 54: 6306–6310.

    PubMed  CAS  Google Scholar 

  81. Israeli RS, Miller WH, Jr, Su SL, Samadi DS, Powell CT, Heston WD, Wise GJ, Fair WR. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol. 1995; 153: 573–577.

    PubMed  CAS  Google Scholar 

  82. Loric S, Dumas F, Eschwege P, Blanchet P, Benoit G, Jardin A, Lacour B. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem. 1995; 41: 1698–1704.

    PubMed  CAS  Google Scholar 

  83. Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, deKernion J, Belldegrun A. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol. 1996; 156: 1560–1566.

    PubMed  CAS  Google Scholar 

  84. Zhang Y, Zippe C D, Van Lente F, Klein EA, Gupta MK. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res. 1997; 3: 1215–1220.

    PubMed  CAS  Google Scholar 

  85. Ghossein RA, Osman I, Bhattacharya S, Ferrara J, Fazzari M, Cordon-Cardo C, Scher HI. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn Mol Pathol. 1999; 8: 59–65.

    PubMed  CAS  Google Scholar 

  86. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O’Toole KM, McMahon D, Benson MC, Buttyan R. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 1994; 43: 765–775.

    CrossRef  PubMed  CAS  Google Scholar 

  87. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol. 1994; 12: 2634–2639.

    PubMed  CAS  Google Scholar 

  88. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol. 1995; 13: 1195–2000.

    PubMed  CAS  Google Scholar 

  89. Henke W, Jung M, Jung K, Lein M, Schlechte H, Berndt C, Rudolph B, Schnorr D, Loening SA. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer. 1997; 70: 52–56.

    CrossRef  PubMed  CAS  Google Scholar 

  90. Wood DP, Jr, Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem. 1994; 42: 505–511.

    PubMed  CAS  Google Scholar 

  91. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res. 1998; 58: 1456–1459.

    PubMed  CAS  Google Scholar 

  92. Mejean A, Vona G, Nalpas B, Damotte D, Brousse N, Chretien Y, Dufour B, Lacour B, Brechot C, Paterlini-Brechot P. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol. 2000; 163: 2022–2029.

    PubMed  CAS  Google Scholar 

  93. Gelmini S, Tricarico C, Vona G, Livi L, Melina AD, Serni S, Cellai E, Magrini S, Villari D, Carini M, Serio M, Forti G, Pazzagli M, Orlando C. Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system. Clin Chem Lab Med. 2001; 39: 385–391.

    CrossRef  PubMed  CAS  Google Scholar 

  94. Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R, Miller K. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using ‘Light-Cycler’-based quantitative real-time polymerase chain reaction. Urology. 2001; 58: 815–820.

    CrossRef  PubMed  CAS  Google Scholar 

  95. De La Taille, Olsson CA, Buttyan R, Benson MC, Bagiella E, Cao Y, Burchardt M, Chopin DK, Katz AE. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. Int J Cancer. 1999; 84: 360–364.

    PubMed  Google Scholar 

  96. Olsson CA, de Vries GM, Raffo AJ, Benson MC, O’Toole K, Cao Y, Buttyan RE, Katz AE. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996; 155: 1557–1562.

    PubMed  CAS  Google Scholar 

  97. De La Taille, Olsson CA, Katz AE. Molecular staging of prostate cancer: dream or reality? Oncology (Huntingt). 1999; 13: 187–194.

    Google Scholar 

  98. Okegawa T, Nutahara K, Higashihara E. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. BJU Int. 1999; 84: 112–117.

    CrossRef  PubMed  CAS  Google Scholar 

  99. Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol. 2001; 19: 3025–3028.

    PubMed  CAS  Google Scholar 

  100. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology. 1997; 50: 100–105.

    CrossRef  PubMed  CAS  Google Scholar 

  101. Hedican SP, Nelson JB, Marshke P, Carter HB, Walsh PC, Partin AW, Luo G, Veltri RW, O’Hara SM. Evaluation of preoperative prostate cancer staging and postoperative detection of recurrence utilizing the reverse transcriptase polymerase chain reaction (RT-PCR). J Urol. 1998; 159(5) suppl: 289, A1115.

    Google Scholar 

  102. van Nguyen C, Song W, Scardino PT, Wheeler TM, Kattan MW, Slawin KM. RT-PCR for PSA and hK2: implications for staging and patient management in men undergoing radical prostatectomy. J Urol. 1998; 159 (5) suppl: 289, A1114.

    Google Scholar 

  103. Gao CL, Maheshwari S, Dean RC, Tatum L, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology. 1999; 53: 714–721.

    CrossRef  PubMed  CAS  Google Scholar 

  104. Laribi A, Berteau P, Gala J, Eschwege P, Benoit G, Tombal B, Schmitt F, Loric S. Blood-borne RT-PCR assay for prostasin-specific transcripts to identify circulating prostate cells in cancer patients. Eur Urol. 2001; 39: 65–71.

    CrossRef  PubMed  CAS  Google Scholar 

  105. Yu JX, Chao L, Chao J. Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994; 269: 18843–18848.

    PubMed  CAS  Google Scholar 

  106. Yu JX, Chao L, Chao J. Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem. 1995; 270: 13483–13489.

    PubMed  CAS  Google Scholar 

  107. Yu JX, Chao L, Ward DC, Chao J. Structure and chromosomal localization of the human prostasin (PRSS8) gene. Genomics. 1996; 32: 334–340.

    CrossRef  PubMed  CAS  Google Scholar 

  108. Meijerink J, Mandigers C, van de LL, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001; 3: 55–61.

    PubMed  CAS  Google Scholar 

  109. Ylikoski A, Sjoroos M, Lundwall A, Karp M, Lovgren T, Lilja H, Iitia, A. Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. Clin Chem. 1999; 45: 1397–1407.

    PubMed  CAS  Google Scholar 

  110. Ylikoski A, Karp M, Pettersson K, Lilja H, Lovgren T. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients. J Mol Diagn. 2001; 3: 111–122.

    PubMed  CAS  Google Scholar 

  111. Ylikoski A, Karp M, Lilja H, Lovgren T. Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes. Biotechniques. 2001; 30: 832–836, 838, 840.

    PubMed  CAS  Google Scholar 

  112. Arfman EW, Gustafson K, Schafer S, Williams EA, Nelson PS, Vessella RL. Isolation by magnetic cell sorting of circulating prostate carcinoma cells in peripheral blood and bone marrow. Cancer Res. 2000; 41 suppl: 316, A2009.

    Google Scholar 

  113. Gauthier LR, Granotier C, Soria JC, Faivre S, Boige V, Raymond E, Boussin FD. Detection of circulating carcinoma cells by telomerase activity. Brit J Cancer. 2001; 84: 631–635.

    PubMed  CAS  Google Scholar 

  114. Sabile A, Louha M, Bonte E, Poussin K, Vona G, Mejean A, Chretien Y, Bougas L, Lacour B, Capron F, Roseto A, Brechot C, Paterlini-Brechot P. Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. Am J Clin Pathol. 1999; 112: 171–178.

    PubMed  CAS  Google Scholar 

  115. Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD, Sabatier L. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 1999; 5: 971–975.

    PubMed  CAS  Google Scholar 

  116. Rosenberg R, Nekarda H, Thorban S, Dahm M, Phelps R, Siewert JR. New density centrifugation method for the enrichment of disseminated tumor cells from peripheral blood. Preliminary results from gastrointestinal cancer patients. Micrometastasis meeting, Hamburg, Germany 2001.

    Google Scholar 

  117. Böckmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng. 2001; 17: 95–111.

    PubMed  Google Scholar 

  118. Colli JL, Ellis WJ, Arfman EW, Lange PH, Vessella RL. The detection and isolation of prostate cancer cells from peripheral blood and bone marrow. J Urol. 2001; 165(5) suppl: 233, A960.

    Google Scholar 

  119. Martin VM, Siewert C, Scharl A, Harms T, Heinze R, Ohl S, Radbruch A, Miltenyi S, Schmitz J. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol. 1998; 26: 252–264.

    PubMed  CAS  Google Scholar 

  120. Lansdorp PM, Thomas TE. Purification and analysis of bispecific tetrameric antibody complexes. Mol Immunol. 1990; 27: 659–666.

    CrossRef  PubMed  CAS  Google Scholar 

  121. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Brit J Cancer. 1987; 56: 714–721.

    PubMed  CAS  Google Scholar 

  122. Leinung S, Wurl P, Weiss CL, Roder I, Schonfelder M. Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg. 2000; 385: 337–343.

    CrossRef  PubMed  CAS  Google Scholar 

  123. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol. 1990; 43: 213–219.

    PubMed  CAS  Google Scholar 

  124. Helfrich W, ten Poele R, Meersma GJ, Mulder NH, de Vries EG, de Leij L, Smit EF. A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. Brit J Cancer. 1997; 76: 29–35.

    PubMed  CAS  Google Scholar 

  125. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000; 156: 57–63.

    PubMed  CAS  Google Scholar 

  126. Brail LH, Jang A, Billia F, Iscove NN, Klamut HJ, Hill RP. Gene expression in individual cells: analysis using global single cell reverse transcription polymerase chain reaction (GSC RT-PCR). Mutat Res. 1999; 406: 45–54.

    PubMed  CAS  Google Scholar 

  127. Harbeck MC, Louie DC, Howland J, Wolf BA, Rothenberg PL. Expression of insulin receptor mRNA and insulin receptor substrate 1 in pancreatic islet beta-cells. Diabetes. 1996; 45: 711–717.

    PubMed  CAS  Google Scholar 

  128. Jena PK, Liu AH, Smith DS, Wysocki LJ. Amplification of genes, single transcripts and cDNA libraries from one cell and direct sequence analysis of amplified products derived from one molecule. J Immunol Methods. 1996; 190: 199–213.

    CrossRef  PubMed  CAS  Google Scholar 

  129. Roudier MP, True LD, Higano CS, Ellis WJ, Lange PH, Vessella RL. Functional and clonal heterogeneity of bone metastatic prostate cancer. J Urol. 2001; 165(5) suppl: 291, A1199.

    Google Scholar 

  130. Pantel K, von Knebel DM. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol. 2000; 12: 95–101.

    CrossRef  PubMed  CAS  Google Scholar 

  131. von Knebel DM, Lacroix J. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metastasis Rev. 1999; 18: 43–64.

    Google Scholar 

  132. Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, Herman JG, Jen J, Sidransky D. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res. 1999; 5: 2450–2454.

    PubMed  CAS  Google Scholar 

  133. Hayashi N, Arakawa H, Nagase H, Yanagisawa A, Kato Y, Ohta H, Takano S, Ogawa M, Nakamura Y. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res. 1994; 54: 3853–3856.

    PubMed  CAS  Google Scholar 

  134. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M, Nakamura Y. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet. 1995; 345: 1257–1259.

    CrossRef  PubMed  CAS  Google Scholar 

  135. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996; 271: 659–662.

    PubMed  CAS  ADS  Google Scholar 

  136. Behn M, Schuermann M. Sensitive detection of p53 gene mutations by a ‘mutant enriched’ PCR-SSCP technique. Nucleic Acids Res. 1998; 26: 1356–1358.

    CrossRef  PubMed  CAS  Google Scholar 

  137. Somers VA, Pietersen AM, Theunissen PH, Thunnissen FB. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol. 1998; 16: 3061–3068.

    PubMed  CAS  Google Scholar 

  138. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst. 1999; 91: 332–339.

    CrossRef  PubMed  CAS  Google Scholar 

  139. Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutantallele-specific amplification (MASA). Hum Mutat. 1993; 2: 112–117.

    CrossRef  PubMed  CAS  Google Scholar 

  140. Austrup F, Uciechowski P, Eder C, Bockmann B, Suchy B, Driesel G, Jackel S, Kusiak I, Grill HJ, Giesing M. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Brit J Cancer. 2000; 83: 1664–1673.

    PubMed  CAS  Google Scholar 

  141. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999; 59: 4180–4184.

    PubMed  CAS  Google Scholar 

  142. Lin B, White JT, Ferguson C, Bumgarner R, Friedman C, Trask B, Ellis W, Lange P, Hood L, Nelson PS. PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res. 2000; 60: 858–863.

    PubMed  CAS  Google Scholar 

  143. Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS. Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Res. 2001; 61: 1611–1618.

    PubMed  CAS  Google Scholar 

  144. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA. 1999; 96: 4494–4499.

    PubMed  CAS  ADS  Google Scholar 

  145. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, Hanahan D, Gray JW. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet. 2001; 29: 459–464.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Washington Medical School, Seattle, USA

    Jesco Pfitzenmaier, Robert L. Vessella, William J. Ellis & Paul H. Lange

Authors
  1. Jesco Pfitzenmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Vessella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William J. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul H. Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Tumour Biology, University Hospital Hamburg-Eppendorf, Germany

    Klaus Pantel (Director) (Director)

Rights and permissions

Reprints and Permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Pfitzenmaier, J., Vessella, R.L., Ellis, W.J., Lange, P.H. (2003). Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow. In: Pantel, K. (eds) Micrometastasis. Cancer Metastasis - Biology and Treatment, vol 5. Springer, Dordrecht. https://doi.org/10.1007/0-306-48355-6_5

Download citation

  • DOI: https://doi.org/10.1007/0-306-48355-6_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-1155-9

  • Online ISBN: 978-0-306-48355-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

search

Navigation